Skip to main content
Premium Trial:

Request an Annual Quote

Pattern Recognition Mass Spec Mania

Premium

GenomeWeb’s latest market research report looks at protein mass-spec technology to figure out what users think of certain instruments and software and how they’re using those in their research. We’ve included a few of the graphs below — find out what your peers are up to and see how your research and results compare to theirs.

Survey respondents told us that protein identification takes up the biggest chunk of their time now, but that in the future they expect that to drop significantly in order for differential proteomics to get more attention.

 

Not surprisingly, the last couple of years have been tough on scientists’ purse-strings. According to respondents, more than a quarter spent absolutely no money on mass spec equipment during the last two years. The outlook’s a little brighter: though again more than 25 percent expect to spend no money, nearly half of all respondents predict they will spend up to half a million dollars on new equipment.

 

NHGRI: Show Us the Money

 

Late last year NHGRI formally announced the establishment of its Large-Scale Sequencing Research Network — but what everyone really wanted to know was which genome centers got how many bucks. The five major centers that applied (the HGP Big Three as well as Venter’s foundation and Agencourt Bioscience) were collectively awarded $163 million for fiscal year ’04, with the same amount planned for 2005 and a drop to $133 million in 2006. That ought to translate to some 54 billion base pairs — or 18 human genomes — over three years.

 

For 2004, here’s how the grants shook out:
Eric Lander, Broad Institute: $59 M
Rick Wilson, Washington University: $49 M
Richard Gibbs, Baylor: $35 M
Doug Smith, Agencourt Bioscience: $10 M
Craig Venter, TIGR: $10 M

 

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.